GSK149203A

PreclinicalBiologic

GSK

GSK149203A is one of 3 biologic programs targeting Cytomegalovirus (CMV). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cytomegalovirus (CMV)Completed

Cytomegalovirus (CMV)Preclinical

Completed

Competition

Competitive Landscape

2 competitors in Cytomegalovirus (CMV)

#DrugCompanyPhaseTrials

Viral Ctls

NNew York Medical College

Phase 2

1 2

VIR-1388

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

1 3

GSK149203A

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cytomegalovirus (CMV)1 trial

Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine

Completed· GSK logo

GSK·N/A·NCT01357915·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GSK149203A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK149203A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK149203A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: GSK

GSK149203A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cytomegalovirus (CMV)1 trial

References

Drug Info

Quick Facts

Related News